Previous 10 | Next 10 |
Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection PR Newswire Clinical registries are collecting real-world clinical utility and clinical validity data on EsoGuard testing in general at-risk populations and fire...
PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference PR Newswire NEW YORK , Sept. 21, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage...
Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection PR Newswire Multicenter observational study documents excellent concordance of EsoGuard results with subsequent medical decision-making by mu...
Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire Fighters PR Newswire Study documents 100 percent concordance between EsoGuard ® test results and subsequent medical decision-making ...
Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit PR Newswire EsoGuard Testing now incorporated in Texas -based Ancira Auto Group's corporate Health and Wellness Program NEW YOR...
PAVmed Provides Business Update and Second Quarter Financial Results PR Newswire EsoGuard ® test volume continues to grow as Lucid makes strides with commercial expansion and additional supporting data Veris Health prepares to launch the next generation of the...
2023-08-15 12:38:03 ET Lucid Diagnostics Inc. (LUCD) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Lishan Aklog - Chairman, CEO Dennis McGrath - EVP, CFO Conference Call Participants Ed Woo - As...
2023-08-15 10:18:04 ET Lucid Diagnostics press release ( NASDAQ: LUCD ): Q2 Non-GAAP EPS of -$0.23 beats by $0.04 . Revenue of $0.16M. For further details see: Lucid Diagnostics Non-GAAP EPS of -$0.23 beats by $0.04, revenue of $0.16M
Lucid Diagnostics Provides Business Update and Second Quarter Financial Results PR Newswire Quarterly EsoGuard ® test volume increased 20 percent sequentially and 159 percent annually Revenue cycle management upgrade completed with immediate positive impact to...
PAVmed to Hold a Business Update Conference Call and Webcast on August 16, 2023 PR Newswire Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , July 31, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "C...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Inc. Company Name:
LUCD Stock Symbol:
NASDAQ Market:
Lucid Diagnostics Inc. Website:
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...